BASEL LIFE 2019

9–12 September 2019

Congress Center Basel
Switzerland

Biotherapeutics

Date

Tuesday 10, September 2019

Chairs

Thomas Huber (Novartis, Switzerland)
Stefan Weigand (Roche, Switzerland)
Renè Assenberg (Janssen Biologics, Netherlands)

Abstract:

Disruptive innovations are driving future biotherapeutics to become more personalized, cost-effective and efficacious. The biotherapeutics are shifting from classical monoclonal antibodies towards more complex modalities, such as engineered antibodies, multi-specific antibodies, cell and gene therapies. The 2019 biotherapeutics forum discusses technology trends and developments required to progress current and future drug modalities from concepts to the market.

 

Tuesday, 10 September 2019

10.00 – 16.30

10.00
Fusion Proteins: Design principles and consequences for manufacturing
Dr. Stefan Schmidt (Bioatrium Visp, CH)

10.30
Master Checkpoint Cbl-b Inhibition: Ambulatory siRNA-based Autologous Cell Therapy for Cancer
Dr. Anderson Gaweco (Apeiron, Vienna, AT)

11.00
Break

11.30
Challenges in CMC development of bispecific antibodies
Dr. Christian Cimander (GenMab, Copenhagen, DK)

12.00
Gene Therapy CMC
Dr. Diane Blumenthal (Spark Therapeutics, Phiadelphia, USA)

12.30
Lunch Break & Industry Symposia


14.00
Co-expression of IgG-like bispecifics for efficient manufacturing
Dr. Michael Bardroff (Novartis, Basel, CH)     

14.30
mRNA as a platform technology ideally suited for individualized therapeutics
Dr. Andreas Kuhn (BioNtech, Mainz, DE)

15.00
Break


15.30
CMC opportunities and challenges in bringing new, complex modalities to the patient
Iedo Beeksma (Janssen Pharmaceuticals, Leiden, NL)

16.00
Audience Q&A with the speakers

Room Samarkand